Diaxonhit, XDx Sign MOU for AlloMap in Europe | GenomeWeb

NEW YORK (GenomeWeb News) – Diaxonhit and XDx today announced that they have signed a memorandum of understanding that would provide an exclusive license to Diaxonhit for XDx's AlloMap Molecular Expression Testing technology in Europe.

As a result, Diaxonhit would become XDx's exclusive partner on the continent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.